肉毒杆菌毒素注射治疗神经源性逼尿肌过度活动的疾病特异性结局
Disease-Specific Outcomes of Botulinum Toxin Injections for Neurogenic Detrusor Overactivity.
作者信息
Kaviani Aaron, Khavari Rose
机构信息
Department of Urology, Houston Methodist Hospital, 6560 Fannin Street, Suite 2100, Houston, TX 77030, USA.
Department of Urology, Houston Methodist Hospital, 6560 Fannin Street, Suite 2100, Houston, TX 77030, USA.
出版信息
Urol Clin North Am. 2017 Aug;44(3):463-474. doi: 10.1016/j.ucl.2017.04.012.
Abstract
Intradetrusor injection of botulinum toxin A (BTX-A) is an effective option for managing patients with neurogenic detrusor overactivity (NDO) who do not respond to or tolerate oral pharmacologic agents. There is level I evidence that intradetrusor injection of onabotulinumtoxinA for refractory NDO in patients with multiple sclerosis and spinal cord injury is associated with a significantly greater achievement of goals and improved performance in urodynamic studies than placebo. Pilot studies or small case series support BTX-A for NDO in patients with Parkinson's disease and cerebrovascular accident. BTX-A seems to be effective in children with myelomeningocele. However, no adult data exists.
摘要
膀胱逼尿肌内注射A型肉毒毒素（BTX-A）是治疗对口服药物无反应或不耐受的神经源性逼尿肌过度活动（NDO）患者的有效选择。有一级证据表明，对于患有多发性硬化症和脊髓损伤的难治性NDO患者，膀胱逼尿肌内注射onabotulinumtoxinA与安慰剂相比，在尿动力学研究中实现目标的可能性显著更高，且性能有所改善。试点研究或小病例系列支持BTX-A用于帕金森病和脑血管意外患者的NDO治疗。BTX-A似乎对脊髓脊膜膨出患儿有效。然而，尚无成人数据。
相似文献
1
Disease-Specific Outcomes of Botulinum Toxin Injections for Neurogenic Detrusor Overactivity.
Urol Clin North Am. 2017 Aug;44(3):463-474. doi: 10.1016/j.ucl.2017.04.012.
2
Meta-analysis of botulinum toxin A detrusor injections in the treatment of neurogenic detrusor overactivity after spinal cord injury.
Arch Phys Med Rehabil. 2013 Aug;94(8):1473-81. doi: 10.1016/j.apmr.2013.04.011. Epub 2013 Apr 28.
3
Long-Term Discontinuation of Botulinum Toxin A Intradetrusor Injections for Neurogenic Detrusor Overactivity: A Multicenter Study.
J Urol. 2019 Apr;201(4):769-776. doi: 10.1016/j.juro.2018.10.012.
4
Less is more-A pilot study evaluating one to three intradetrusor sites for injection of OnabotulinumtoxinA for neurogenic and idiopathic detrusor overactivity.
Neurourol Urodyn. 2017 Apr;36(4):1104-1107. doi: 10.1002/nau.23052. Epub 2016 Jun 10.
5
Use of botulinum toxin in individuals with neurogenic detrusor overactivity: state of the art review.
J Spinal Cord Med. 2013 Sep;36(5):402-19. doi: 10.1179/2045772313Y.0000000116.
6
[Intradetrusor injections of botulinum toxin A to treat urinary incontinence due to bladder overactivity during idiopathic Parkinson's disease].
Prog Urol. 2021 Jun;31(7):430-438. doi: 10.1016/j.purol.2021.01.004. Epub 2021 Feb 9.
7
Impairment of sensory afferents by intrathecal administration of botulinum toxin A improves neurogenic detrusor overactivity in chronic spinal cord injured rats.
Exp Neurol. 2016 Nov;285(Pt B):159-166. doi: 10.1016/j.expneurol.2016.05.029. Epub 2016 May 25.
8
Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review.
Eur Urol. 2008 Feb;53(2):275-87. doi: 10.1016/j.eururo.2007.10.013. Epub 2007 Oct 16.
9
Switch to Abobotulinum toxin A may be useful in the treatment of neurogenic detrusor overactivity when intradetrusor injections of Onabotulinum toxin A failed.
Neurourol Urodyn. 2018 Jan;37(1):291-297. doi: 10.1002/nau.23291. Epub 2017 Apr 21.
10
More Than 15 Years of Experience with Intradetrusor OnabotulinumtoxinA Injections for Treating Refractory Neurogenic Detrusor Overactivity: Lessons to Be Learned.
Eur Urol. 2016 Sep;70(3):522-8. doi: 10.1016/j.eururo.2016.03.052. Epub 2016 Apr 19.
引用本文的文献
1
The Efficiency of Rehabilitation Therapy in Patients Diagnosed with Neurogenic Bladder: A Systematic Review.
Medicina (Kaunas). 2024 Jul 17;60(7):1152. doi: 10.3390/medicina60071152.
2
Lower urinary tract dysfunction in the central nervous system neurogenic bladder and the real-life treatment outcome of botulinum toxin A.
Tzu Chi Med J. 2024 May 24;36(3):260-270. doi: 10.4103/tcmj.tcmj_29_24. eCollection 2024 Jul-Sep.
3
Voiding Phase Dysfunction in Multiple Sclerosis: Contemporary Review of Terminology, Diagnosis, Management, and Future Directions.
Urol Clin North Am. 2024 May;51(2):177-185. doi: 10.1016/j.ucl.2024.01.005. Epub 2024 Mar 4.
4
Real-Life Treatment Outcome of Botulinum Toxin A Injection on Overactive Bladder and Voiding Dysfunction in Patients with Central Nervous System Lesions.
Toxins (Basel). 2024 Mar 1;16(3):123. doi: 10.3390/toxins16030123.
5
Quality of Life in Female Patients with Overactive Bladder after Botulinum Toxin Treatment.
Toxins (Basel). 2023 Dec 21;16(1):7. doi: 10.3390/toxins16010007.
6
Efficacy of Tibial Nerve Stimulation in Neurogenic Lower Urinary Tract Dysfunction Among Patients with Multiple Sclerosis: A Systematic Review and Meta-analysis.
Urol Res Pract. 2023 Mar;49(2):100-111. doi: 10.5152/tud.2023.22241.
7
Effects of tibial and parasacral nerve electrostimulation techniques on women with poststroke overactive bladder: study protocol for a randomized controlled trial.
Trials. 2020 Nov 19;21(1):936. doi: 10.1186/s13063-020-04856-4.
8
Efficacy and safety of intradetrusor onabotulinumtoxinA injection for managing paediatric non-neurogenic overactive bladder: A prospective case-series study.
Arab J Urol. 2019 Apr 24;17(2):143-149. doi: 10.1080/2090598X.2019.1600993. eCollection 2019.
9
Botulinum Neurotoxin, an Example of Successful Translational Research.
Clin Pharmacol Transl Med. 2018;2(3):125-126. Epub 2018 Oct 19.
10
Urinary symptoms, quality of life, and patient satisfaction in genetic and sporadic hereditary spastic paraplegia.
J Neurol. 2019 Jan;266(1):207-211. doi: 10.1007/s00415-018-9129-8. Epub 2018 Nov 22.
本文引用的文献
1
Management of Overactive Bladder With OnabotulinumtoxinA: Systematic Review and Meta-analysis.
Urology. 2017 Feb;100:53-58. doi: 10.1016/j.urology.2016.10.026. Epub 2016 Oct 24.
2
Outcomes of intra-detrusor injections of botulinum toxin in patients with spina bifida: A systematic review.
Neurourol Urodyn. 2017 Mar;36(3):557-564. doi: 10.1002/nau.23025. Epub 2016 May 17.
3
Neurogenic lower urinary tract dysfunction: Clinical management recommendations of the Neurologic Incontinence committee of the fifth International Consultation on Incontinence 2013.
Neurourol Urodyn. 2016 Aug;35(6):657-65. doi: 10.1002/nau.23027. Epub 2016 May 13.
4
More Than 15 Years of Experience with Intradetrusor OnabotulinumtoxinA Injections for Treating Refractory Neurogenic Detrusor Overactivity: Lessons to Be Learned.
Eur Urol. 2016 Sep;70(3):522-8. doi: 10.1016/j.eururo.2016.03.052. Epub 2016 Apr 19.
5
Long-Term Efficacy and Safety of OnabotulinumtoxinA in Patients with Neurogenic Detrusor Overactivity Who Completed 4 Years of Treatment.
J Urol. 2016 Sep;196(3):801-8. doi: 10.1016/j.juro.2016.04.046. Epub 2016 Jun 2.
6
Association Between Anticholinergic Medication Use and Cognition, Brain Metabolism, and Brain Atrophy in Cognitively Normal Older Adults.
JAMA Neurol. 2016 Jun 1;73(6):721-32. doi: 10.1001/jamaneurol.2016.0580.
7
Management of neurogenic bladder in patients with multiple sclerosis.
Nat Rev Urol. 2016 May;13(5):275-88. doi: 10.1038/nrurol.2016.53. Epub 2016 Mar 31.
8
Use of Botulinum Toxin A in the Treatment of Lower Urinary Tract Disorders: A Review of the Literature.
Toxins (Basel). 2016 Mar 23;8(4):88. doi: 10.3390/toxins8040088.
9
Reduction in Bladder-Related Autonomic Dysreflexia after OnabotulinumtoxinA Treatment in Spinal Cord Injury.
J Neurotrauma. 2016 Sep 15;33(18):1651-7. doi: 10.1089/neu.2015.4278. Epub 2016 Apr 13.
10
Urinary tract infections in multiple sclerosis.
Mult Scler. 2016 Jun;22(7):855-61. doi: 10.1177/1352458516633903. Epub 2016 Feb 18.
Zotero 插件